大学ホーム医学研究科教育・研究指導教員紹介:

教員紹介:永根 基雄


氏名
 
永根 基雄
ナガネ モトオ NAGANE, Motoo
職位 教授
学内の役職・委員等 杏林大学医学部付属病院がんセンター副センター長
所属教室
専攻・専門分野
 (大学院)
担当科目(学部) 脳腫瘍
担当科目(大学院) 脳神経腫瘍学
兼務・兼担 実験動物施設部門長
専門分野 悪性脳腫瘍、分子生物学
研究テーマ 悪性脳腫瘍の治療、化学療法、薬剤耐性、分子生物学、臨床試験
略歴 1984年 東京大学医学部医学科卒
1990年 日本脳神経外科学会専門医
1991年 国立がんセンター中央病院脳神経外科医員
1994年 東京大学医学部医学博士
1995年-2000年 Ludwig Institute for Cancer Research at San Diego, CA, U.S.A.にてpostdoctoral fellow.2000年 杏林大学医学部脳神経外科講師
2005年 同助教授.
2007年 同准教授.
2012年 同臨床教授
所有する学位 博士(医学)
指導医・専門医・認定医、その他の資格等 日本脳神経外科学会脳神経外科専門医・指導医、日本がん治療認定医機構暫定教育医・がん治療認定医
論文・著書等を含む主要研究業績 原著
1. Nagane M. Preface for Brain Tumor Pathology vol. 41 issue 2 (Special issue for the 41st Annual Meeting of the Japan Society of Brain Tumor Pathology). Brain Tumor Pathol Published online 01 April, 2024, https://doi.org/10.1007/s10014-024-00479-8
2. Yonezawa H, Narita Y, Nagane M, et al. Three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-Oncol Adv, vdae037, https://doi.org/10.1093/noajnl/vdae037, Published:22 April 2024
3. Takami H, Satomi K, Nagane M, et al. Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors.
Sci Rep 2023 Sep 21;13(1):15760. doi: 10.1038/s41598-023-42842-3.
4. Fukuoka K; Kurihara J; Nagane M; et al. Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: A Japanese Pediatric Molecular Neuro-Oncology Group study. Acta Neuropathol Commun 2023 Sep 25;11(1):153. doi: 10.1186/s40478-023-01652-4.
5. Arakawa Y, Narita Y, Nagane M, et al. Karnofsky Performance Status and Quality of Life in Patients with Relapsed or Refractory Primary CNS Lymphoma from a Phase I/II Study of Tirabrutinib. Neuro-Oncol Adv vdad109, https://doi.org/10.1093/noajnl/vdad109 Published: 14 September 2023
6. Satomi K, Saito K, Nagane M, Shibahara J, et al. The role of nonlinear dimension reduction of genome‐wide DNA methylome in integrated diagnosis: A case study of glioblastoma, IDH‐wildtype. Pathology International DOI: 10.1111/pin.13359. First published: 02 August 2023
7. Hibiya T, Nagane M, Shibahara J, et al. Epstein-Barr virus-positive monoclonal lymphoplasmacytic proliferation associated with neurosyphilis in an immunocompetent patient: a case report. Neuropathology published: 09 July 2023. https://doi.org/10.1111/neup.12934
8. Weller M, Nagane M, Preusser M et al. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. Neuro Oncol. 25(7):1200-1224. (2023).
9. Shima Y, Nagane M, Nakatomi H et al. Increased PDGFRB and NF-κB signaling caused by highly prevalent somatic mutations in intracranial aneurysms. Sci Trans Med 2023 Jun 14;15(700):eabq7721. doi: 10.1126/scitranslmed.abq7721. Epub 2023 Jun 14
10. Mishima M, Nagane M, et al. Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C. Neuro Oncol 25(4):687-698, 2023.
11. Nagane M, Ichimura K, Nishikawa R et al. Bevacizumab Beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers 2022, 14 (22), 5522. https://doi.org/10.3390/cancers14225522
12. Ohno M, Kitanaka C, Nagane M, Narita Y, et al. Phase I Study of Metformin with Temozolomide for Newly-diagnosed Glioblastoma Patients and Review of a Targeted Therapy for Cancer stem/initiating cells by Metformin. Cancers 2022, 14, 4222. https://doi.org/10.3390/ cancers14174222
13. Takami H, Nagane M, Ichimura K, et al. Transcriptome and Methylome Analysis of CNS Germ Cell Tumor Finds Its Cell-of-Origin in Embryogenesis and Reveals Mutual Characters with Testicular Counterparts. Neuro-Oncol 24 (8):1246-1258, 2022.
14. Habiba U, Nagane M, Tanaka S et al. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study. Acta Neuropathol Commun. 2021 May 21;9(1):95. doi: 10.1186/s40478-021-01194-7.PMID: 34020723
15. Satomi K, Nagane M, Ichimura K et al.; on behalf of The Intracranial Germ Cell Tumor Genome Analysis Consortium (The iGCT Consortium). 12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. Neuro-Oncol 2021 Oct 26;noab246. doi: 10.1093/neuonc/noab246. Online ahead of print.
16. Yamagishi Y, Nagane M, Ichimura K et al. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. Cancer Sci 112:4702–4710, 2021
17. Narita Y, Nagane M, Mishima K et al. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A Non-randomized, Phase 1/2 Trial. Cancer Sci 112 (12):5020-5033, 2021. DOI.org/10.1111/cas.15153. First published: 05 October 2021
18. Aoki T, Nagane M, Nishikawa R et al. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. Int J Clin Oncol Published online; 29 September 2021. https://doi.org/10.1007/s10147-021-02028-1
19. Takami H, Nagane M, Ichimura K et al. on behalf of the Intracranial Germ Cell Tumor Genome Analysis Consortium (the iGCT Consortium). Low tumor cell content predicts favorable prognosis in germinoma patients. Neuro-Oncol Adv 3(1):vdab110. 2021 Aug 10. doi: 10.1093/noajnl/vdab110. eCollection Jan-Dec 202
20. Barajas RF, Nagane M, Hu LS et al. Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lymphoma: Guideline Statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 23(7):1056-1071, 2021. 2021 Feb 9;noab020. doi: 10.1093/neuonc/noab020
21. Kanamori M, Nagane M, Nishikawa R et al. Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging - A controversy. Neuro-Oncol Adv 2021 Jun 25;3(1):vdab086. doi: 10.1093/noajnl/vdab086. eCollection Jan-Dec 2021.
22. Fujimoto K, Nagane M, Ichimura K et al. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol Published online: 20 June 2021. https://doi.org/10.1007/s00401-021-02337-9
23. Takahashi S, Nagane M, Hamamoto R et al. Fine-tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. Cancers 13 (6):1415, 2021, DOI 10.3390/cancers13061415
24. Narita Y, Nagane M, Nishikawa R et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro-Oncol 23(1):122-133, 2021. 2020 Jun 25; noaa145. doi: 10.1093/neuonc/noaa145
25. Kitahama K, Nagane M, Shibahara J et al. Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors. Brain Tumor Pathol 38:23-29, 2021. Published online: 28 September 2020, DOI 10.1007/s10014-020-00382-y
26. Arita H, Nagane M, N Ichimura K et al. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in lower grade gliomas with IDH1/2 mutations. Acta Neuropathol Com (2020) 8:201 https://doi.org/10.1186/s40478-020-01078-2
27. Tateishi K, Nagane M, Yamamoto T et al. A hyperactive RelA/p65-hexokinase 2 signaling axis drives primary central nervous system lymphoma. Cancer Res 80(23):5330-5343, 2020. (Dec 1) 2020 Oct 16;canres.2425.2020. doi: 10.1158/0008-5472.CAN-20-2425.
28. Kanamori M, Nagane M, Nishikawa R et al. So-called “bifocal tumors” with diabetes insipidus and negative tumor markers: Are they all germinoma? Neuro-Oncol 2020 Aug 20;noaa199. doi: 10.1093/neuonc/noaa199. Online ahead of print
29. Tabei Y, Nagane M et al. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status. Jpn J Clin Oncol 51(1):45-53, 2021. 2020 Sep 5;hyaa162. doi: 10.1093/jjco/hyaa162
30. Nakano Y, Nagane M, Ichimura K et al.: Utility of a bridged nucleic acid clamp for liquid biopsy: detecting BRAF V600E in the cerebrospinal fluid of a patient with brain tumor. Pediatric Blood & Cancer DOI:10.1002/pbc.28651. First published: 09 August 2020
31. Sasaki N, Nagane M et al. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Jpn J Clin Oncol 50(9):999-1008, 2020. doi: 10.1093/jjco/hyaa073
32. Natsume A, Nagane M, Wakabayashi T, et al. and members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG). Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. J Neurooncol 2020 May;148(1):17-27. doi: 10.1007/s11060-020-03505-9. Epub 2020 May 4
33. Guerreiro Stucklin AS, Nagane M, Hawkins C et al.: Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Comm. 2019 Sep 25;10(1):4343. doi: 10.1038/s41467-019-12187-5
34. Takami H, Nagane M, Ichimura K et al.: Integrated Clinical, Histopathological, and Molecular Data Analysis of 190 Central Nervous System Germ Cell Tumors from the iGCT Consortium. Neuro-Oncol 2019 Dec 17;21(12):1565-1577. doi: 10.1093/neuonc/noz139.
35. Nagane M, Nishikawa R et al.: Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study. Jpn J Clin Oncol 49 (11):1016-1023, 2019. 2019 Oct 28. pii: hyz125. doi: 10.1093/jjco/hyz125. [Epub ahead of print]
36. Takami H, Nagane M, Ichimura K et al. on behalf of the Intracranial Germ Cell Tumor Genome Analysis Consortium (the iGCT Consortium): Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance. Neuropathology and Applied Neurobiology 2020 Feb;46(2):111-124. doi: 10.1111/nan.12570. Epub 2019 Jul 29
37. Nejo T, Nagane M, Kakimi K et al.: Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma. Cancer Immunol Res. 2019 Jul;7(7):1148-1161. doi: 10.1158/2326-6066.CIR-18-0599. Epub 2019 May 14.
38. Nomura M, Nagane M, Mukasa A et al.: DNA demethylation is associated with malignant progression of lower-grade gliomas. Scientific Reports 9: 1903-1914, 2019. | https://doi.org/10.1038/s41598-019-38510-0
39. Narita Y, Nagane M, Terasaki M et al.: A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Neuro-Oncology 21 (3): 348-359, 2019. https://doi.org/10.1093/neuonc/noy200 published: 30 November 2018
40. Kayama T, Nagane M, Shibui S, et al. and Japan Clinical Oncology Group. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): A Phase III, noninferiority, randomized controlled trial. J Clin Oncol 36:3282-3289, 2018. doi: 10.1200/JCO.2018.78.6186.
41. Fukuoka K, Nagane M; Ichimura K et al.: Significance of molecular classification in ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogenous group of tumor. Acta Neuropathol Comm 6:134, 2018. https://doi.org/10.1186/s40478-018-0630-1
42. Iijima S, Nagane M et al.: Hepatosplenic gamma-delta T cell lymphoma involving the brain. World Neurosurg 118: 139-142, 2018. doi: 10.1016/j.wneu.2018.07.048. Epub 2018 Jul 18.
43. Wakabayashi T, Nagane M, Shibui S et al.: JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neuro-oncol 2018 Jul;138(3):627-636. doi: 10.1007/s11060-018-2831-7. Epub 2018 Mar 20
44. Takano S, Nagane M, Matsumura A et al.: MyD88 mutation in elderly predicts poor prognosis in primary central nervous system lymphoma; multi-institutional analysis. World Neurosurg 2017 Dec 16. pii: S1878-8750(17)32144-7. doi: 10.1016/j.wneu.2017.12.028. [Epub ahead of print]
45. Maruyama K, Nagane M, Shiokawa Y et al.: Smart glasses for neurosurgical navigation by augmented reality. Operative Neurosurgery 15:551-556, 2018, https://doi.org/10.1093/ons/opx279 Published: 24 January 2018
46. Nomura M, Nagane M, Saito N et al.: Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathol 134: 941-956, 2017. DOI 10.1007/s00401-017-1771-1
47. Wang W, Nagane M, Cheng C et al.: Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A. Proc Natl Acad Sci 114(31):8366-8371, 2017 Aug 1. doi: 10.1073/pnas.1701289114. Epub 2017 Jul 17
48. Lee J, Nagane M et al.: Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy. Jpn J Clin Oncol 47(10):925-934, 2017. 2017 Oct 1, doi: 10.1093/jjco/hyx098.
49. Aihara K, Nagane M, Saito N et al.: Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol Comm 5: 18, 2017. DOI 10.1186/s40478-017-0422-z
50. Fukushima S, Nagane M, Ichimura K et al. On behalf of The Intracranial Germ Cell Tumor Genome Analysis Consortium (The iGCTConsortium): Genome‑wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. Acta Neuropathol 133: 445-462, 2017. DOI 10.1007/s00401-017-1673-2, published online; 11 January 2017
51. 山岸 夢希, 永根 基雄ら:高齢者膠芽腫に対する術後放射線治療および化学療法の選択と予後に関する検討.Geriatric Neurosurgery 29: 25-37, 2017
52. Nakamura T, Nagane M, Ichimura K et al.: Genome-wide DNA methylation profiling identifies primary central nervous system lymphomas as a distinct entity from systemic diffuse large B-cell lymphomas. Acta Neuropathol (Feb) 133(2):321-324, 2017. doi: 10.1007/s00401-016-1664-8. Epub 2017 Jan 5
53. Yamagishi Y, Nagane M et al.: Black hairy tongue after chemotherapy for malignant brain tumors. Acta Neurochir 159: 169-172, 2017. Published online: 23 November 2016. doi:10.1007/s00701-016-3036-5
54. Arita H, Nagane M, Ichimura K et al.: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications 4:79, 2016, DOI 10.1186/s40478-016-0351-2.
55. 久米賢,永根基雄ら: 神経膠腫における 1H-Magnetic Resonance Spectroscopy (MRS)とLCModelを用いた2-hydroxyglutarate (2-HG)検出及びその定量的解析.杏林医会誌 47 (3): s21-25, 2016
56. 永山和樹, 永根基雄, 塩川芳昭ら:杏林大学における転移性脳腫瘍に対するLINAC 定位放射線治療16 年間の経験. 定位的放射線治療20: 103-112, 2016.
57. Ichimura K, Nagane M, Nishikawa R et al., The Intracranial Germ Cell Tumor Genome Analysis Consortium: Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathol 131: 889-901, 2016. Published online: 08 March 2016. DOI 10.1007/s00401-016-1557-x.
58. Tsuchihashi K, Nagane M, Nagano O et al.: The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Res 76 (10): 2954-2963, 2016. Published Online First March 15, 2016; doi: 10.1158/0008-5472.CAN-15-2121
59. Furuse M, Nagane M, Miyatake S et al.: A prospective multicenter single-arm clinical trial of bevacizumab for patients with surgically untreatable symptomatic brain radiation necrosis. Neuro-Oncol Practice 3(4), 272–280, 2016. doi:10.1093/nop/npv064
60. Fukumura K, Nagane M, Mano H et al.: Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol 131: 865-875, 2016. publish online 12 Jan 2016, DOI 10.1007/s00401-016-1536-2.
61. Nitta Y, Nagane M et al.: Nimotuzumab enhances temozolomide induced growth suppression of glioma cells expressing mutant EGFR in vivo. Cancer Med 5 (3): 486-499, 2016. 2016 Jan 18. doi: 10.1002/cam4.614. [Epub ahead of print]
62. Nagane M, Shiokawa Y et al. Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro-Oncology 12: 687-700, 2010
63. Nagane M, Shiokawa Y et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly-diagnosed glioblastoma---analysis of O6-methylguanine-DNA methyltransferase status. J Neuro-Oncol 92: 227-232, 2009
64. Nagane M, Shiokawa Y et al. Combined treatment with histone deacetylase inhibitors enhances cytotoxic activity of anti-DR5/TRAIL-R2 monoclonal antibodies in human glioma cells (Abst). Neuro-Oncology 10 (5): 788-789, 2008

総説
1. 小林啓一,永根基雄:再発膠芽腫の治療戦略.脳神経外科ジャーナル Jpn J Neurosurg(Tokyo)33 (2):96-104, 2024
2. 永根基雄. 中枢神経系原発悪性リンパ腫の病態と治療開発:最近の動向と展望. 臨床血液63(9):1145-1156, 2022
3. 永根基雄:中枢神経系原発悪性リンパ腫に対する標的治療. Precision Medicine 5 (7):18-21, 2022.
4. Batchelor T, Nagane M, et al.: Primary diffuse large B-cell lymphoma of immune-privileged sites. In World Health Organization (WHO) Classification of Haematolymphoid Tumours. 5th Edition. Dave SS, de Jong D, Moch H (Eds), International Agency for Research on Cancer, Lyon, 2021 (published online first).
5. Batchelor T, Nagane M, et al. Haematolymphoid tumours involving the CNS. Lymphomas. In World Health Organization (WHO) Classification of the Central Nervous System Tumours. 5th Edition. Brat DJ, Ellison DW, et al. (Eds), International Agency for Research on Cancer, Lyon, 2021 (published online first).
6. 永根基雄:中枢神経系原発におけるBTK阻害薬選択の考え方と注意点. 血液内科82 (6): 782-789, 2021.
7. 永根基雄:中枢神経系原発悪性リンパ腫. In 希少がん—がん診療の新たな課題—.川井章(編),日本臨牀 79(増刊1):Pp207-212, 2021,
8. 永根基雄:中枢神経系原発悪性リンパ腫. in 脳神経外科学II [改訂13版].松谷雅生(総編集),金芳堂, 京都, pp1714-1739, 2020
9. 永根基雄:膠芽腫. in 脳神経外科学II [改訂13版].松谷雅生(総編集),金芳堂, 京都, pp1591-1628 2020
10. 永根基雄:中枢神経系原発悪性リンパ腫.In 脳腫瘍診療ガイドライン 改訂第2版(2019年版),日本脳腫瘍学会(編), 金原出版, 東京, Pp 107-155, 2019
11. 永根基雄:中枢神経系のリンパ腫.In 悪性リンパ腫治療マニュアル(改訂第5版),永井宏和,山口素子,丸山大(編),南江堂,東京, Pp222-226, 2020
12. 永根基雄:PCNSL治療の最近のトレンドについて.日本医事新報5029:51, 2020(2020年09月12日発行)
13. 永根基雄:中枢神経系原発びまん性大細胞型B細胞リンパ腫. In 特殊または稀少な造血器腫瘍に対する診断・病態と治療. 血液内科80 (5): 623-635, 2020.
14. 永根基雄:Neuro-Oncology最新のトピックス:初発退形成性星細胞腫に対するCATNON試験結果 – ASCO 2019より.IMEウェブサイト『Neurodiem』日本語版https://www.neurodiem.jp/news/neuro-oncology-catnon-asco-2019-XCO5WmT3na5EbSwnmyG1h
15. 永根基雄:悪性脳腫瘍の診断と治療.Jpn J Rehabil Med(リハ医学)56 (8):602-608, 2019
16. 永根基雄:中枢神経系悪性リンパ腫の治療開発−多剤併用薬物療法及び新規分子標的治療薬.最新医学73 (11): 1441-1449, 2018
17. 永根基雄:中枢神経系悪性腫瘍.日本癌治療学会会誌52 (1): 181-183, 2017
18. 成田善孝,永根基雄ら:JCOG脳腫瘍グループによる悪性脳腫瘍に対する臨床試験.脳神経外科ジャーナル,25 巻 (2016) 7 号 p. 566-578
19. 永根基雄:中枢神経系原発悪性リンパ腫.In 脳腫瘍診療ガイドライン 2016年版,日本脳腫瘍学会(編), 金原出版, 東京, Pp 97-128, 2016
20. 永根基雄: 悪性リンパ腫. In EBMに基づく脳神経疾患の基本治療指針 第4版. 田村晃,松谷雅生,清水輝夫,辻貞俊,塩川芳昭,成田善孝(編),メジカルビュー社,東京,Pp126-136, 2016
21. Nagane M: Dose-dense temozolomide – Is it still promising? Neurol Med Chir (Tokyo) 55: 38-49, 2015, doi: 10.2176/nmc.ra.2014-0277, online December 20, 2014
22. Nagane M, Nishikawa R: Bevacizumab for glioblastoma – a promising drug or not? Cancers 5(4): 1456-1468, 2013; doi:10.3390/cancers5041456.
23. Nagane, M: Recent progress in Neuro-oncology. J Jpn S Clin Oncol 46 (3): 1344-1347, 2011
24. Nagane M. Multidisciplinary progress in neuro-oncology 2010.Lancet Neurol 10 (1): 18-20, 2011
25. Nagane M, Cavenee WK, Huang H-JS. The Potential of TRAIL for Cancer Chemotherapy. Apoptosis 6: 191-197, 2001
26. Nagane M, Lin H, Cavenee WK, Huang H-JS. Aberrant receptor signaling in human malignant gliomas: Mechanisms and therapeutic implications. Cancer Lett 162 Suppl 1:S17-S21, 2001
27. Cavenee WK, Nagane M, et al. Diffuse Astrocytomas. In Pathology and Genetics of Tumours of the Nervous System, Second Edition. (P. Kleihues and W. Cavenee, eds.) IARC Press, Lyon, France, 2000. p. 10-21
28. Nagane M, Huang H-J S, & Cavenee W K: Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug Resistance Updates 2: 30-37, 1999
29. Nagane M, Huang H-J S, & Cavenee W K: Advances in the molecular genetics of gliomas. Cur Opin Oncol 9 (3): 215-222, 1997

競争的研究資金獲得歴(研究代表者のみ)
平成13年度
1. 科学研究費補助金 基盤研究(C)
研究課題名「悪性グリオーマにおけるTRAIL・抗癌剤併用による細胞死の分子機構の解明」
研究代表者 永根基雄
研究期間 平成13-14年度

平成15年度
2. 科学研究費補助金 基盤研究(C)
研究課題名「脳腫瘍における中性アミノ酸トランスポーター発現の生物学的意義及び新規治療法の開発」
研究代表者 永根基雄
研究期間 平成15-16年度

平成17年度
3.科学研究費補助金(基盤研究C)
研究課題名「悪性神経膠腫に対するヒト抗TRAIL受容体抗体による新規治療法の開発」
研究者代表者:永根基雄
研究期間 平成17-18年度

平成19年度
4.科学研究費補助金(基盤研究C)
研究課題名 「悪性神経膠腫に対する複合的シグナル阻害剤による新規治療法の開発」
研究者代表者:永根基雄
研究期間 平成19-21年度

平成22年度
5.科学研究費補助金(基盤研究C)
研究課題名 「悪性神経膠腫に対する新規抗EGFR抗体・抗癌剤併用による治療法の開発」
研究者代表者:永根基雄
研究期間 平成22-24年度

平成25年度
6.科学研究費補助金(基盤研究C)
研究課題名 「悪性神経膠腫に対するDNA修復機構阻害による抗癌剤増感治療法の開発」
研究者代表者:永根基雄
研究期間 平成25-27年度

平成28年度
7.科学研究費補助金(基盤研究B)
研究課題名 「中枢神経系悪性リンパ腫に特異的な遺伝子異常の機能解析と新規分子標的治療の開発」
研究者代表者:永根基雄
研究期間 平成28-31年度

平成29年度
8. 日本医療研究開発機構(革新的がん医療実用化研究事業):
研究開発課題名 「再発膠芽腫に対するテモゾロミド用量強化法を用いた標準治療確立に関する研究」
研究開発代表者:永根基雄
委託期間 平成29-31年度

令和2(2020)年度
9. 科学研究費補助金(基盤研究B)
研究課題名「中枢神経系悪性リンパ腫の腫瘍内多様性と微小環境解析による病態発生の解明と治療開発」
研究者代表者:永根基雄
研究期間 令和2年-5年度
所属学会 日本脳神経外科学会(代議員)、日本脳腫瘍学会(理事長)、米国臨床腫瘍学会(ASCO)、アメリカ癌学会(AACR)、北米脳腫瘍学会(SNO)、欧州脳腫瘍学会(EANO)、アジア脳腫瘍学会(ASNO)(Audit委員会副委員長)、日本癌学会、日本癌治療学会、日本臨床腫瘍学会(評議員)、日本脳腫瘍病理学会(理事)など
公的な委員会等の役員・委員歴 日本脳腫瘍学会理事長、日本臨床腫瘍学会協議員、日本がん治療学会代議員、独立行政法人医薬品医療機器総合機構(PMDA)専門委員、日本癌治療学会がん診療ガイドライン統括・連絡委員会評価委員(脳腫瘍担当)
学外活動Neuro-Oncology誌のAssociate Editor、Jpn J Clin OncolしのAssociate Editor
学生のみなさんへ 脳を中心とした中枢神経系疾患を扱う脳神経外科領域の中で、特に悪性脳腫瘍を専門としています。脳に発生する原発性脳腫瘍と他臓器のがんから転移してくる転移性脳腫瘍があります。前者の原発性脳腫瘍には手術で摘出することで治癒が望める良性脳腫瘍と、極めて悪性度が高く現在の医学をもってしてもほとんど致死的な膠芽腫をはじめとした悪性脳腫瘍があります。膠芽腫を含め国内、海外の研究者と協力してその病態解明、有効な新規治療開発を多施設共同研究や臨床試験、治験等を多数実施しています。ヒトの中枢である脳という未だ神秘なベールに包まれている特殊臓器に発生する難治疾患に是非興味を頂いて頂ければ幸いです。
このページのトップへ

PAGE TOP